Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Cyprotex Announces a Collaborative Research Agreement with Pfizer

Published: Friday, November 02, 2012
Last Updated: Friday, November 02, 2012
Bookmark and Share
The deal extends over an eighteen month period and is split into two stages with the second stage being dependent on certain milestones being achieved.

The collaboration is a research-based project which the parties aim to evaluate, further develop, and improve several of Cyprotex’s proprietary offerings in the area of predictive toxicology.

Dr. Anthony Baxter, Cyprotex’s Chief Executive Officer, comments on the collaboration: “We are delighted to be able to continue our relationship with Pfizer. This collaborative research is beneficial for both companies and allows Cyprotex to remain at the forefront of new approaches in toxicology prediction. Predicting drug-induced toxicity is a challenging field, and we are making significant advances by combining our knowledge with that of our partners and clients.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cyprotex Appoints Dr Rob Elsby as Leader of Drug Transporter Team
Cyprotex PLC has appointed Dr Rob Elsby as Leader of its Drug Transporter Team.
Wednesday, March 18, 2015
Cyprotex Acquires CeeTox
Auquistion broadens toxicological assay and screening capabilities to the cosmetic and personal care industry.
Thursday, January 02, 2014
Cyprotex Launch Updated Drug-Drug Interaction Regulatory Guidance
Booklet to reflect the new FDA and EMA guidelines.
Friday, August 17, 2012
Sygnature Discovery and Cyprotex Extend Successful Strategic Alliance
The companies have announced they have entered into an extension of their highly successful partnership for a further 2 years.
Monday, December 19, 2011
Cyprotex Extends Cloe® Screen Mechanism-Based Inhibition Service to Include 4 Additional Cytochrome P450 Isoforms
New assays compliment the CYP3A4 isoform assay which was launched last year.
Friday, March 30, 2007
Scientific News
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Tension Helps Heart Cells Develop Normally in the Lab
Stanford engineers have uncovered the important role tension plays in growing heart cells out of the body.
Controlling Body Temperature in Response to 'Fight or Flight'
New research in The FASEB Journal suggests that blocking TRPV1 protein causes an increased release of noradrenaline, leading to an increase in core body temperatures.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A Fundamental Protection Mechanism Against Formalin In Mammals is Revealed
Formaldehyde, or formalin, is well known to all of us as a common chemical used in many industrial processes and also as a preservative, remarkably we also produce formaldehyde in our bodies.
Drug Used To Treat HIV Linked to Lower Bone Mass in Newborns
NIH study finds mothers’ use of tenofovir tied to lower bone mineral content in babies.
Bone Risks Linked to Genetic Variants
A large-scale genomic study uncovered novel genetic variants and led researchers to an unexpected gene that affects bone density and fracture risk.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos